<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01917175</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 1220/12277 PRECO-CI</org_study_id>
    <nct_id>NCT01917175</nct_id>
  </id_info>
  <brief_title>Early Identification and Treatment of Early HIV Infection in Côte d'Ivoire</brief_title>
  <acronym>PRECO-CI</acronym>
  <official_title>Research Platform &quot; Early Identification and Treatment of Early HIV Infection in Côte d'Ivoire &quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ANRS, Emerging Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ANRS, Emerging Infectious Diseases</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Set-up of a biobank for patients with an estimated date of infection seroconverters: store&#xD;
      plasma and cells samples at initial contact and during follow-up for future analysis and&#xD;
      analysis in international collaborative cohort seroconverters.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1997</start_date>
  <completion_date type="Actual">September 2018</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Natural history of HIV infection in Sub-Saharan Africa</measure>
    <time_frame>12 months after ART initiation</time_frame>
    <description>Plasmatic HIV viral load and CD4 measured every six months and incidence of morbidity events associated with AIDS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimate the probability of disease progression after HIV seroconversion</measure>
    <time_frame>12 months after ART initiation</time_frame>
    <description>Disease progression will be estimated with CD4 cell loss and time from seroconversion to clinical AIDS, death and antiretroviral therapy initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of markers of HIV infection and immunity</measure>
    <time_frame>12 months after ART initiation</time_frame>
    <description>CD4 count, immune activation, plasma HIV-RNA intracellular, HIV-DNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral genetic diversity description</measure>
    <time_frame>Inclusion (J0)</time_frame>
    <description>biomolecular analysis of HIV-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary resistance to antiretroviral treatment</measure>
    <time_frame>Inclusion (J0)</time_frame>
    <description>Frequency of primary resistance to antiretroviral treatment (genotyping)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic and lipodystrophic disorders</measure>
    <time_frame>12 months after ART initiation</time_frame>
    <description>Metabolic analysis (Total Cholesterol, HDL and LDL, Triglycerides) and lipodystrophia measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pregnancies</measure>
    <time_frame>12 months after ART initiation</time_frame>
    <description>Occurence of pregnancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T lymphocytes activation and evolution in seroconverters</measure>
    <time_frame>Inclusion</time_frame>
    <description>Define parameters of activation of T lymphocytes and their evolution since primo-infection among individuals recently infected in West Africa; Expression of markers CD38, HLA-DR, CD28 and CD127 on CD4 and CD8 T cells by flux cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T lymphocytes activation and evolution in seroconverters</measure>
    <time_frame>12 months after ART initiation</time_frame>
    <description>Define parameters of activation of T lymphocytes and their evolution since primo-infection among individuals recently infected in West Africa; Expression of markers CD38, HLA-DR, CD28 and CD127 on CD4 and CD8 T cells by flux cytometry</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">511</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>HIV+ patients with an estimated date of seroconversion</arm_group_label>
    <description>It was estimated that 564 individuals, will be enrolled at the Blood Bank Medical Centre, including 364 individuals already followed-up (former PRIMOCI ANRS 1220 cohort started in 1997) and 200 newly enrolled individuals in this study.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma and whole blood for PBMC preparation&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All HIV infected individuals that will have had a contact with the Blood Bank Medical&#xD;
        Center since 1992.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients included in the last Primo-CI ANRS 1220 protocol&#xD;
&#xD;
          -  All HIV infected individuals diagnosed during a blood donation with an estimated date&#xD;
             of HIV seroconversion that will respect the following criteria: (i) age ≥18 (ii) HIV-1&#xD;
             or HIV-1+2 infected, (iii) HIV-seronegative at the preceding donation; (iv) who&#xD;
             returned to the clinic to be informed of their HIV test result (v) with an HIV&#xD;
             serology confirmed with two specific tests in two different laboratories (vi) who have&#xD;
             never received ART for curative purpose&#xD;
&#xD;
          -  informed on study objectives and have a signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient living outside of Abidjan&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Kla Minga, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CMSDS, Abidjan, Côte d'Ivoire</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Coffie, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Programme PACCI, Abidjan, Côte d'Ivoire</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charlotte Lewden, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Bordeaux, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Médical du Suivi des Donneurs de Sang (Blood Bank Medical Centre)</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre National de Transfusion Sanguine (National Blood Transfusion Centre)</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Côte D'Ivoire</country>
  </location_countries>
  <link>
    <url>http://anrs.fr/</url>
    <description>Sponsor site</description>
  </link>
  <link>
    <url>http://mereva.net</url>
    <description>Methodology centre site</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 5, 2013</study_first_submitted>
  <study_first_submitted_qc>August 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2013</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Cohort</keyword>
  <keyword>Early HIV infection</keyword>
  <keyword>Côte d'Ivoire</keyword>
  <keyword>Disease progression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

